According to the HHS guidelines, an ARV regimen for a treatment-naive patient generally consists of a dual NRTI regimen administered in combination with a third active ARV drug from one of three drug classes: an INSTI, a NNRTI, or a PI with a PK enhancer. The use of the INSTI dolutegravir, plus the NRTI lamivudine, is also recommended in certain patient populations (see below). Recommended initial regimens include:
Bictegravir/tenofovir alafenamide/emtricitabine
Dolutegravir/abacavir/lamivudine — only for individuals who are HLA-B*5701 negative and without chronic hepatitis B virus (HBV) coinfection
Dolutegravir plus (emtricitabine or lamivudine) plus (tenofovir alafenamide or tenofovir disoproxil fumarate)
Dolutegravir/lamivudine — except for individuals with HIV RNA > 500,000 copies/mL, HBV co-infection, or in whom ART is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available
Raltegravir plus (emtricitabine or lamivudine) plus (tenofovir alafenamide [TAF] or tenofovir disoproxil fumarate [TDF])
For additional information, refer to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV.
Learn more about HIV treatment approaches.
Editor's Recommendations
Medscape © 2021 WebMD, LLC
Cite this: Michael Stuart Bronze, Nicholas J. Bennett. Fast Five Quiz: How Much Do You Know About HIV? - Medscape - May 10, 2021.
Comments